Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpression in IPF lung tissues. We herein developed a series of novelhHDAC6 inhibitors, having low inhibitory potency overhHDAC1 andhHDAC8, as potential pharmacological tools for IPF treatment. Their inhibitory potency was combined with lowin vitroandin vivotoxicity. Structural analysis of 6h and structure-activity relationship studies contributed to the optimization of the binding mode of the new molecules. The best-performing analogues were tested for their efficacy in inhibiting fibrotic sphere formation and cell viability, proving their capability in reverting the IPF phenotype. The efficacy of analogue 6h was also determined in a validated human lung model of TGF-?1-dependent fibrogenesis. The results highlighted in this manuscript may pave the way for the identification of first-in-class molecules for the treatment of IPF.
Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors
Tedesco Daniele;Ruberti Giovina;Saccoccia Fulvio;
2021
Abstract
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease characterized by a progressive-fibrosing phenotype. IPF has been associated with aberrant HDAC activities confirmed by our immunohistochemistry studies on HDAC6 overexpression in IPF lung tissues. We herein developed a series of novelhHDAC6 inhibitors, having low inhibitory potency overhHDAC1 andhHDAC8, as potential pharmacological tools for IPF treatment. Their inhibitory potency was combined with lowin vitroandin vivotoxicity. Structural analysis of 6h and structure-activity relationship studies contributed to the optimization of the binding mode of the new molecules. The best-performing analogues were tested for their efficacy in inhibiting fibrotic sphere formation and cell viability, proving their capability in reverting the IPF phenotype. The efficacy of analogue 6h was also determined in a validated human lung model of TGF-?1-dependent fibrogenesis. The results highlighted in this manuscript may pave the way for the identification of first-in-class molecules for the treatment of IPF.File | Dimensione | Formato | |
---|---|---|---|
prod_456112-doc_199196.pdf
Open Access dal 13/07/2022
Descrizione: 032_2021-jmc-64_9960_postprint
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
1.95 MB
Formato
Adobe PDF
|
1.95 MB | Adobe PDF | Visualizza/Apri |
prod_456112-doc_195761.pdf
Open Access dal 13/07/2022
Descrizione: 2021-jmc-64_9960_supp1
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
4.59 MB
Formato
Adobe PDF
|
4.59 MB | Adobe PDF | Visualizza/Apri |
prod_456112-doc_195762.zip
Open Access dal 13/07/2022
Descrizione: 2021-jmc-64_9960_supp2
Tipologia:
Documento in Post-print
Licenza:
Creative commons
Dimensione
146.07 kB
Formato
Unknown
|
146.07 kB | Unknown | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.